Navigation Links
Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
Date:3/28/2013

RARITAN, N.J., March 28, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for simeprevir (TMC435), an investigational NS3/4A protease inhibitor, administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients.

"Hepatitis C is a complicated disease and genotype 1 hepatitis C can be particularly difficult to cure. Given the complexity and diversity of the patient population, physicians need multiple options to provide their patients a chance at treatment success," said Wim Parys , Global Head of Development, Infectious Diseases and Vaccines, Janssen. "The U.S. filing represents an important step forward in bringing simeprevir to market and in helping to battle this challenging disease."

Hepatitis C virus (HCV) is a blood-borne infectious disease of the liver that affects approximately 3.2 million people in the United States. When left untreated over time, HCV can cause significant damage to the liver, including cirrhosis.

The regulatory submission for simeprevir is supported in part by data from three pivotal Phase 3 studies: QUEST-1 and QUEST-2 in treatment-naïve patients and PROMISE in patients who have relapsed after prior interferon-based treatment. In each study, participants were treated with one 150 mg simeprevir capsule once daily for 12 weeks plus pegylated interferon and ribavirin for 24 or 48 weeks. Primary efficacy data from the Phase 3 studies will be presented at an upcoming medical meeting.

About Simeprevir
Simeprevir (TMC435) is an investigational NS3/4A protease inhibitor jointly developed by Janssen and Medivir AB for the treatment of genotype 1 chronic hepatitis C in adult patients with com
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
2. Janssen Pharmaceutica, NV, Funds New Global Mental Health Scholarships as Part of Its Healthy Minds Program
3. Janssen Neuroscientists and Colleagues Challenge Healthcare Industry to Create Integrated Approaches to Healthcare Innovation in Newly Published Article
4. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
5. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
6. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
9. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
10. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
11. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... Disorders Drug Pipeline Insight 2014" report to their offering. ... in US is one of the largest segments of pharmaceuticals ... alarming rate, while the available therapies were unable to meet ... in the market for CNS disorder, especially over the past ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Development Trend Forecast of Pharmaceutical Equipment Market in China, ... Research and Development Trend Forecast of Pharmaceutical Equipment Market ... China,s pharmaceutical equipment industry in ... competition landscape, and business performance of domestic major enterprises, ...
(Date:8/29/2014)... , August 29, 2014 ... Market by Product & Services (Equipment, Reagent, Primer, ... Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, ... MarketsandMarkets, the global Oligonucleotide Synthesis Market is expected ... Million in 2014, growing at a CAGR of ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... Company to present interim results from phase 2 trial of novel ... ... NEW HAVEN, Conn., April 3, 2008 Rib-X Pharmaceuticals,Inc. ("Rib-X" ... of novel antibiotics for the treatment of,antibiotic-resistant infections, today announced that ...
... Proof-of-Principle Studies -, GAITHERSBURG, Md., April 3, ... announced that it has signed an agreement,with Merck ... the use of the Iomai needle-free immunostimulant patch., ... exclusive license. These,preclinical proof-of-principle studies will be conducted ...
Cached Medicine Technology:Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference 2Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch 2Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch 3
(Date:8/29/2014)... UWDress.com, one of the most famous dress ... of 2014 floor length bridesmaid dresses . Additionally, ... items. According to the company’s marketing specialist, all its ... rate (up to 60 percent off) before September 10. ... special neckline: strapless, one-shoulder, bateau and more. The main ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 According to new ... But Not Peer Pressure, Key to Prescription Drug Misuse Among ... primary focus for 18-29 year olds when it comes to ... the for this age group the real problem which influences ... drug associations and recreational use of them to have fun ...
(Date:8/29/2014)... Healthpointe is proud to welcome to ... will be practicing out of Healthpointe’s newest office directly ... Healthpointe’s orthopedic team, Dr. Rodas is board-certified ... in occupational medicine. , Among Dr. Rodas’ many ... of Raytheon, the world-class defense and aerospace company. Additionally, ...
(Date:8/29/2014)... regarded audiologist , Dr. Mary Ann Larkin has written 4 ... are titled:, , Revealing the Truth About Tinnitus ... The Top 5 Things You Should Know Before Buying a ... , Dr. Mary Anne Larkin choose to write about ... misinformation about each them. The reports are available for immediate ...
(Date:8/29/2014)... Healthpointe Medical Group, one of Southern California’s ... LAXMed. The medical center is less than 2 miles from ... the 405 freeway. , The LAX clinic marks the ... is located at: 8610 S. Sepulveda Blvd., Suite 204 Los ... LAX office will provide the same comprehensive services as Healthpointe’s ...
Breaking Medicine News(10 mins):Health News:2014 Floor Length Bridesmaid Dresses for Sale at UWDress.com 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Dr. Anthony G. Rodas Joins Healthpointe Team at LAX Office 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 3Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2
... ... Pediatric Surgery , ... 16, 2009 -- Children,s National Medical Center today announced that it will create a new ... of Abu Dhabi. , , ,"This is a great day for Children,s National, but it,s ...
... , Pocono Medical Center and facilities ... of laboratory errors due to specimen mislabeling , ... northeast Pennsylvania have come together to reduce and eliminate laboratory errors ... effort when they noticed they were reporting a large number of ...
... FORT LAUDERDALE, Fla. and BEVERLY HILLS, Calif., Sept. 16 As ... for ways to supplement their income. In response, a new ... event at the Sofitel Hotel in Beverly Hills to introduce its ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090916/NY76803 ) , (Logo: ...
... , , , WASHINGTON, ... by U.S. Senate Finance Committee Chairman Max Baucus (D-MT) will ... health coverage, while letting insurance companies charge what they please ... the most successful insurance premium regulation law in the nation, ...
... , , ... Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced ... Trademark Office has issued a Notice of Allowance for Milestone,s ... Dynamic Pressure Sensing." , , ...
... ... CSL), one of the world,s leading manufacturers of influenza vaccine, announced that the U.S. ... licensure of its monovalent pandemic (H1N1) 2009 influenza A vaccine for active immunization of ... , ...
Cached Medicine News:Health News:New Surgery Institute at Children's National Medical Center Aims to Improve Surgery and Eliminate Pain 2Health News:New Surgery Institute at Children's National Medical Center Aims to Improve Surgery and Eliminate Pain 3Health News:New Surgery Institute at Children's National Medical Center Aims to Improve Surgery and Eliminate Pain 4Health News:Pennsylvania Patient Safety Authority Releases September Advisory 2Health News:Pennsylvania Patient Safety Authority Releases September Advisory 3Health News:Pennsylvania Patient Safety Authority Releases September Advisory 4Health News:Pennsylvania Patient Safety Authority Releases September Advisory 5Health News:livethesource(TM) Hosts Company Launch Event While Supporting The Brent Shapiro Foundation's Annual Sober Night Out 2Health News:livethesource(TM) Hosts Company Launch Event While Supporting The Brent Shapiro Foundation's Annual Sober Night Out 3Health News:Baucus Health Plan Won't Rein in Health Insurer Price Gouging of Middle Class; Consumer Watchdog Calls for 'Prior Approval' Rate Regulation in Health Reform 2Health News:Baucus Health Plan Won't Rein in Health Insurer Price Gouging of Middle Class; Consumer Watchdog Calls for 'Prior Approval' Rate Regulation in Health Reform 3Health News:Milestone Scientific Receives Notice of Allowance From U.S. Patent and Trademark Office 2Health News:Milestone Scientific Receives Notice of Allowance From U.S. Patent and Trademark Office 3Health News:Milestone Scientific Receives Notice of Allowance From U.S. Patent and Trademark Office 4Health News:CSL Biotherapies Announces FDA Marketing Approval of its Monovalent Pandemic (H1N1) 2009 Influenza A Vaccine 2
... American Industrial Laboratories, Inc. specializes in ... eyebank and laboratory specular microscopes, digital ... camera digital upgrade package. Our software ... image data correlation with rapid image ...
... management software is a full-featured product ... clinical aspects of the ophthalmic practice. ... for the financial, administrative and clinical ... professional. Designed as a scaleable solution, ...
The ReSeeVit Slit Lamp System is an easy-to-use digital video imaging system that captures anterior segment and retinal images for documentation, diagnosis and patient education. The package includes...
... The 2V slit lamp ... slit lamp that is ... illumination tower and has ... magnification. Revolutionary design provides ...
Medicine Products: